News | July 28, 2025
GSK forges $12 billion alliance with Hengrui Pharma
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
The new Zigly center features and offers comprehensive veterinary services
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Subscribe To Our Newsletter & Stay Updated
